Voyager Therapeutics Inc (NASDAQ:VYGR) — Market Cap & Net Worth
Market Cap & Net Worth: Voyager Therapeutics Inc (VYGR)
Voyager Therapeutics Inc (NASDAQ:VYGR) has a market capitalization of $149.01 Million ($149.01 Million) as of September 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17730 globally and #4177 in its home market, demonstrating a -11.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Voyager Therapeutics Inc's stock price $2.68 by its total outstanding shares 55600084 (55.60 Million). Also see VYGR total asset value for a full breakdown of the balance sheet.
Voyager Therapeutics Inc Market Cap History: 2015 to 2026
Voyager Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $1.22 Billion to $149.01 Million (-15.95% CAGR). Also see VYGR cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Voyager Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.01% | #487 of 976 |
|
NASDAQ Composite
IXIC
|
$42.21 Trillion | 0.00% | #1729 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.87 Trillion | 0.01% | #233 of 263 |
Weight: Voyager Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Voyager Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Voyager Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Voyager Therapeutics Inc (VYGR) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.94x
Voyager Therapeutics Inc's market cap is 3.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.22 Billion | $17.33 Million | -$29.67 Million | 70.25x | N/A |
| 2016 | $708.35 Million | $14.22 Million | -$40.19 Million | 49.81x | N/A |
| 2017 | $922.96 Million | $10.13 Million | -$70.70 Million | 91.07x | N/A |
| 2018 | $522.64 Million | $7.62 Million | -$88.29 Million | 68.60x | N/A |
| 2019 | $775.62 Million | $104.39 Million | -$40.83 Million | 7.43x | N/A |
| 2020 | $397.54 Million | $171.13 Million | $36.74 Million | 2.32x | 10.82x |
| 2021 | $150.68 Million | $37.41 Million | -$66.03 Million | 4.03x | N/A |
| 2022 | $339.16 Million | $40.91 Million | -$46.41 Million | 8.29x | N/A |
| 2023 | $469.26 Million | $250.01 Million | $132.33 Million | 1.88x | 3.55x |
| 2024 | $315.25 Million | $80.00 Million | -$65.00 Million | 3.94x | N/A |
Competitor Companies of VYGR by Market Capitalization
Companies near Voyager Therapeutics Inc in the global market cap rankings as of September 26, 2026. Review Voyager Therapeutics Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Voyager Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Voyager Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Voyager Therapeutics Inc's market cap moved from $1.22 Billion to $ 149.01 Million, with a yearly change of -15.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $149.01 Million | -31.81% |
| 2025 | $218.51 Million | -30.69% |
| 2024 | $315.25 Million | -32.82% |
| 2023 | $469.26 Million | +38.36% |
| 2022 | $339.16 Million | +125.09% |
| 2021 | $150.68 Million | -62.10% |
| 2020 | $397.54 Million | -48.75% |
| 2019 | $775.62 Million | +48.40% |
| 2018 | $522.64 Million | -43.37% |
| 2017 | $922.96 Million | +30.30% |
| 2016 | $708.35 Million | -41.83% |
| 2015 | $1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 26th, 2026 the market cap of Voyager Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $149.01 Million USD |
| MoneyControl | $149.01 Million USD |
| MarketWatch | $149.01 Million USD |
| marketcap.company | $149.01 Million USD |
| Reuters | $149.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more